Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-09-07
2008-05-27
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C544S284000, C544S357000
Reexamination Certificate
active
07378422
ABSTRACT:
The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
REFERENCES:
patent: 5484801 (1996-01-01), Al-Razzak et al.
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5948436 (1999-09-01), Al-Razzak et al.
patent: 5990276 (1999-11-01), Zhang et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6054472 (2000-04-01), Armistead et al.
patent: 6344465 (2002-02-01), Armistead et al.
patent: 6498178 (2002-12-01), Stamos et al.
patent: 6541496 (2003-04-01), Armistead et al.
patent: 2003/0236242 (2003-12-01), Perni et al.
patent: 2004/0018986 (2004-01-01), Pitlik et al.
patent: 2005/0080017 (2005-04-01), Cottrell et al.
patent: 2005/0090450 (2005-04-01), Farmer et al.
patent: WO 94/14436 (1994-07-01), None
patent: WO 95/07696 (1995-03-01), None
patent: WO 95/09614 (1995-04-01), None
patent: WO 97/40028 (1997-10-01), None
patent: WO 97/43310 (1997-11-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/40381 (1998-09-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/64442 (1999-12-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/56331 (2000-09-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 01/07407 (2001-02-01), None
patent: WO 01/32691 (2001-05-01), None
patent: WO 01/40262 (2001-06-01), None
patent: WO 01/58929 (2001-08-01), None
patent: WO 01/64678 (2001-09-01), None
patent: WO 01/64678 (2001-09-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 02/07761 (2002-01-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 02/48116 (2002-06-01), None
patent: WO 02/48157 (2002-06-01), None
patent: WO 02/48157 (2002-06-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 03/087092 (2003-10-01), None
patent: WO 03/087092 (2003-10-01), None
patent: WO 03087092 (2003-10-01), None
patent: WO 2004/092161 (2004-10-01), None
Gettins, et al. “Serpin Structure, Mechanism, and Function” Chem. Rev., 2002, 102, 4751-4803.
Alberti et al., “Natural History of Hepatitis C”,J. Hepatology, 31: 17-24 (1999).
Alter et al., “The Epidemiology of Viral Hepatitis in the United States”,Gastroenterol. Clin. North Am., 23:437-455 (1994).
Alter, “Hepatitis C Virus Infection in the United States”,J. Hepatology, 31: 88-91 (1999).
Bartenschlager et al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions”,J. Virol., 67: 3835-3844 (1993).
Beaulieu and Llinàs-Brunet, “Therapies for Hepatitis C Infection: Targeting the Non-Structural Proteins”,Current Medicinal Chemistry-Anti-Infective Agents, 1: 163-176 (2002).
Di Bisceglie and Hoofnagle, “Optimal Therapy of Hepatitis C”,Hepatology, 36: S121-S127 (2002).
Chambers et al., “Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus Is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein”,Proc. Natl. Acad. Sci. USA, 87: 8898-8902 (1990).
Choo et al., “Genetic Organization and Diversity of the Hepatitis C Virus”,Proc. Natl. Acad. Sci. USA, 88: 2451-2455 (1991).
Clayette et al., “IFN-T, A New Type I IFN with Antiretroviral Activity”,Pathol. Biol. (Paris), 47: 553-559 (1999).
Davis et al., “Future Options for the Management of Hepatitis C.”,Seminars in Liver Disease, 19: 103-112 (1999).
Dunsdon et al., “Solid Phase Synthesis of Aminoboronic Acids: Potent Inhibitors of the Hepatitis C Virus NS3 Proteinase”,Bioorg. Med. Chem. Lett., 10: 1577-1579 (2000).
Dymock, “Emerging Therapies for Hepatitis C Virus Infections”,Emerging Drugs, 6: 13-42 (2001).
Grakoui et al., “Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products”,J. Virol., 67: 1385-1395 (1993).
Grakoui et al., “Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites”,J. Virol., 67: 2832-2843 (1993).
Han et al., “α-Ketoamides, α-Ketoesters and α-Diketones as HCV NS3 Protease Inhibitors”,Bioorg. Med. Chem. Lett., 10: 711-713 (2000).
Heathcote et al. “Peginterferon Alpha-2a in Patients with Chronic Hepatitis C and Cirrhosis”,New England Journal of Medicine, 343: 1673-1680 (2000).
Iwarson, “The Natural Course of Chronic Hepatitis”,FEMS Microbiology Reviews, 14: 201-204 (1994).
Janssen et al., “Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis”,J. Hepatol., 21: 241-243 (1994).
Kao et al., “Efficacy of Consensus Interferon in the Treatement of Chronic Hepatitis”,J. Gastroenterol. Hepatol. 15: 1418-1423 (2000).
Kato et al., “Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis C”,Proc. Natl. Acad. Sci. USA, 87: 9524-9528 (1990).
Kew, “Hepatitis C and Hepatocellular Carcinoma”,FEMS Microbiology Reviews, 14: 211-219 (1994).
LaPlante et al., “NMR Line-Broadening and Transferred Noesy as a Medicinal Chemistry Tool for Studying Inhibitors of the Hepatitis C Virus NS3 Protease Domain”,Bioorg. Med. Chem. Lett., 10: 2271-2274 (2000).
Lavanchy, “Global Surveillance and Control of Hepatitis C”,J. Viral Hepatitis, 6: 35-47 (1999).
Lin et al., “Hepatitis C Virus NS3 Serine Proteinase:Trans-Cleavage Requirements and Processing Kinetics”,J. Virol., 68: 8147-8157 (1994).
Lipinski, “Bioisosteres in Drug Design”,Annual Reports in Medicinal Chemistry, 21: 286-288 (1986).
Llinàs-Brunet et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease”,Bioorg. Med. Chem. Lett., 8: 1713-1718 (1998).
Llinàs-Brunet et al., “Highly Potent and Selective Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease: Towards Smaller Inhibitors”,Bioorg. Med. Chem. Lett., 10: 2267-2270 (2000).
Markland et al., “Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: A Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon”,Antimicrobial&Antiviral Chemotherapy, 44: 859-866 (2000).
Moradpour et al., “Current and Evolving Therapies for Hepatitis C”,Eur. J. Gastroenterol. Hepatol., 11: 1199-1202 (1999).
Reddy et al. “Efficacy and Safety of Pegylated (40-kd) Interferon α-2a Compared with Interferon α-2a in Noncirrhoti
Britt Shawn D.
Court John J.
Perni Robert B.
Pitlik Janos
van Drie John H.
Haley Jr. James F.
Kercher Michele A.
Nolan Jason M
Ropes & Gray LLP
Saeed Kamal A.
LandOfFree
Inhibitors of serine proteases, particularly HCV NS3-NS4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of serine proteases, particularly HCV NS3-NS4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine proteases, particularly HCV NS3-NS4A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3983124